Signe E. Cremer

Signe E. Cremer

Auto-generated profile, based on publicly available information

Signe E. Cremer

Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
SCS.E. Cremer
S.E. Cremer
GSG.E. Singletary
G.E. Singletary
LOLisbeth Høier Olsen
Lisbeth Høier Olsen
KWK. Wallace
K. Wallace
JHJens Häggström
Jens Häggström
MOM.A. Oyama
M.A. Oyama
Hypothesis/Objectives: Altered serotonin (5-hydroxytryptamine, 5HT) signaling is postulated in development and progression of canine myxomatous mitral valve disease (MMVD). Little is known regarding platelet, plasma, valvular, or myocardial 5HT concentration ([5HT]) in affected dogs. We quantified [5HT] in platelet-rich plasma (PRP), platelet-poor plasma (PPP), mitral valve leaflets (MV), and left ventricular myocardium (LV). Animals: Forty-five dogs comprised 4 plasma groups of Cavalier King Charles Spaniels (CKCS) or non-CKCS, either healthy (CON) or MMVD affected: CKCS CON (n = 12); non-CKCS CON (n = 8); CKCS MMVD (n = 14); non-CKCS MMVD (n = 11). Twenty-four dogs comprised 3 tissue groups: MMVD (n = 8); other-HD (heart disease) (n = 7); non-HD, extracardiac disease (n = 9). Methods: High-performance liquid chromatography measured PRP, PPP, MV, and LV [5HT]. Results: Platelet-rich plasma platelet [5HT] was greater in CKCS CON (1.83 femtograms/platelet [fg/plt]; range, 0.20–4.76; P = .002), CKCS MMVD (1.58 fg/plt; range, 0.70–4.03; P = .005), and non-CKCS MMVD (1.72 fg/plt; range, 0.85–4.44; P = .003) versus non-CKCS CON (0.92 fg/plt; range, 0.63–1.30). There was no group difference in PPP [5HT]. MV [5HT] was significantly higher in MMVD (32.4 ng/mg; range, 8.4–106.7) versus non-HD (3.6 ng/mg; range, 0–28.3; P = .01) and LV [5HT] was significantly higher in MMVD (11.9 ng/mg; range, 4.0–104.8) versus other-HD (0.9 ng/mg; range, 0–10.1; P = .011) and non-HD (2.5 ng/mg; range, 0–6.9; P = .001). Conclusions and Clinical Importance: Platelet [5HT] was highest in healthy CKCS and both MMVD groups, but plasma [5HT] showed no group differences. Tissue [5HT] was highest in MV and LV of MMVD-affected dogs, suggesting altered 5HT signaling as a potential feature of MMVD. Interactions of platelet, valvular, and myocardial 5HT signaling warrant further investigation.

1 June 2015 in Research in Veterinary Science
Verified
Journal Article
Closed access
SCS.E. Cremer
S.E. Cremer
SMS.G. Moesgaard
S.G. Moesgaard
CRC.E. Rasmussen
C.E. Rasmussen
NZN.E. Zois
N.E. Zois
TFT. Falk
T. Falk
LOLisbeth Høier Olsen
Lisbeth Høier Olsen

1 February 2015 in The Veterinary Journal
Verified
Journal Article
Closed access
SCS.E. Cremer
S.E. Cremer
NZN.E. Zois
N.E. Zois
SMS.G. Moesgaard
S.G. Moesgaard
NRN. Ravn
N. Ravn
SCS. Cirera
S. Cirera
LOLisbeth Høier Olsen
Lisbeth Høier Olsen

1 June 2015 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
SCSigne E. Cremer
Signe E. Cremer
AKAnnemarie T. Kristensen
Annemarie T. Kristensen
MRMaria J. Reimann
Maria J. Reimann
NENynne B. Eriksen
Nynne B. Eriksen
SPStine F. Petersen
Stine F. Petersen
LOLisbeth Høier Olsen
Lisbeth Høier Olsen
OBJECTIVE To investigate serum and plasma serotonin concentrations, percentage of serotonin-positive platelets, level of surface-bound platelet serotonin expression (mean fluorescence intensity [MFI]), and platelet activation (CD62 expression) in platelet-rich plasma from Cavalier King Charles Spaniels with myxomatous mitral valve disease (MMVD). ANIMALS Healthy dogs (n = 15) and dogs with mild MMVD (18), moderate-severe MMVD (19), or severe MMVD with congestive heart failure (CHF; 10). PROCEDURES Blood samples were collected from each dog. Serum and plasma serotonin concentrations were measured with an ELISA, and surface-bound platelet serotonin expression and platelet activation were determined by flow cytometry. RESULTS Dogs with mild MMVD had higher median serum (746 ng/mL) and plasma (33.3 ng/mL) serotonin concentrations, compared with MMVD-affected dogs with CHF (388 ng/mL and 9.9 ng/mL, respectively), but no other group differences were found. Among disease groups, no differences in surface-bound serotonin expression or platelet activation were found. Thrombocytopenic dogs had lower serum serotonin concentration (482 ng/mL) than nonthrombocytopenic dogs (731 ng/mL). In 26 dogs, a flow cytometry scatterplot subpopulation (FSSP) of platelets was identified; dogs with an FSSP had a higher percentage of serotonin-positive platelets (11.0%), higher level of surface-bound serotonin expression (MFI, 32,068), and higher platelet activation (MFI, 2,363) than did dogs without an FSSP (5.7%, 1,230, and 1,165, respectively). An FSSP was present in 93.8% of thrombocytopenic dogs and in 29.5% of nonthrombocytopenic dogs. CONCLUSIONS AND CLINICAL RELEVANCE A substantive influence of circulating serotonin on MMVD stages prior to CHF development in Cavalier King Charles Spaniels was not supported by the study findings. An FSSP of highly activated platelets with pronounced serotonin binding was strongly associated with thrombocytopenia but not MMVD.

13 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SCSigne E Cremer
Signe E Cremer
JCJames L Catalfamo
James L Catalfamo
RGRobert Goggs
Robert Goggs
ESErnst Stefan Seemann
Ernst Stefan Seemann
AKAnnemarie T Kristensen
Annemarie T Kristensen
MBMarjory B Brooks
Marjory B Brooks
Domestic dogs share the same environment as humans, and they represent a valuable animal model to study naturally-occurring human disease. Platelet proteomics holds promise for the discovery of biomarkers that capture the contribution of platelets to the pathophysiology of many disease states, however, canine platelet proteomic studies are lacking. Our study objectives were to establish a protocol for proteomic identification and quantification of the thrombin-activated canine platelet secretome (CAPS), and to compare the CAPS proteins to human and murine platelet proteomic data. Washed platelets were isolated from healthy dogs, and stimulated with saline (control) or gamma-thrombin (releasate). Proteins were separated by SDS-page, trypsin-digested and analyzed by liquid chromatography and tandem mass spectrometry (MS). CAPS proteins were defined as those with a MS1-abundance ratio of two or more for releasate vs. unstimulated saline control. A total of 1,918 proteins were identified, with 908 proteins common to all dogs and 693 characterized as CAPS proteins. CAPS proteins were similar to human and murine platelet secretomes and were highly represented in hemostatic pathways. Differences unique to CAPS included replacement of platelet factor 4 with other cleavage products of platelet basic protein (e.g. interleukin-8), novel proteins (e.g. C-C motif chemokine 14), and proteins in relatively high (e.g. protease nexin-1) or low (e.g. von Willebrand factor) abundance. This study establishes the first in-depth platelet releasate proteome from healthy dogs with a reference database of 693 CAPS proteins. Similarities between CAPS and the human secretome confirm the utility of dogs as translational models of human disease, but we also identify differences unique to canine platelets. Our findings provide a resource for further investigations into disease-related CAPS profiles, and for comparative pathway analyses of platelet activation among species.

3 December 2020 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SCSigne E. Cremer
Signe E. Cremer
JCJames L. Catalfamo
James L. Catalfamo
RGRobert Goggs
Robert Goggs
SSStefan E. Seemann
Stefan E. Seemann
AKAnnemarie T. Kristensen
Annemarie T. Kristensen
MBMarjory B. Brooks
Marjory B. Brooks
Background Domestic dogs represent a translational animal model to study naturally occurring human disease. Proteomics has emerged as a promising tool for characterizing human platelet pathophysiology; thus a detailed characterization of the core canine activated platelet secretome (CAPS) will enhance utilization of the canine model. The objectives of this study were development of a robust, high throughput, label‐free approach for proteomic identification and quantification of the canine platelet (i) thrombin releasate proteins, and (ii) the protein subgroup that constitutes CAPS. Methods Platelets were isolated from 10 healthy dogs and stimulated with 50 nmol/L of γ‐thrombin or saline. Proteins were in‐solution trypsin‐digested and analyzed by nano–liquid chromatography–tandem spectrometry. Core releasate proteins were defined as those present in 10 of 10 dogs, and CAPS defined as releasate proteins with a significantly higher abundance in stimulated versus saline controls (corrected P < .05). Results A total of 2865 proteins were identified; 1126 releasate proteins were present in all dogs, 650 were defined as CAPS. Among the differences from human platelets were a canine lack of platelet factor 4 and vascular endothelial growth factor C, and a 10‐ to 20‐fold lower concentration of proteins such as haptoglobin, alpha‐2 macroglobulin, von Willebrand factor, and amyloid‐beta A4. Twenty‐eight CAPS proteins, including cytokines, adhesion molecules, granule proteins, and calcium regulatory proteins have not previously been attributed to human platelets. Conclusions CAPS proteins represent a robust characterization of a large animal platelet secretome and a novel tool to model platelet physiology, pathophysiology, and to identify translational biomarkers of platelet‐mediated disease.